| Drug Type Biosimilar, Colony-stimulating factors | 
| Synonyms Filgrastim  Biosimilar (Tanvex BioPharma, Inc.), 非格司亭 生物类似药(Tanvex BioPharma, Inc.), TX-01 + [1] | 
| Target | 
| Action agonists | 
| Mechanism CSF-3R agonists(Colony stimulating factor 3 receptor agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization | 
| Drug Highest PhaseApproved | 
| First Approval Date Canada (01 Oct 2021),  | 
| Regulation- | 

| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | Filgrastim-txid | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Febrile Neutropenia | United States  | 28 Jun 2024 | |
| Stem cell mobilisation | United States  | 28 Jun 2024 | |
| Neutropenia | Canada  | 01 Oct 2021 | 






